SeekingAlpha · Sep 16, 2026
InMode: Reasonably Valued But With Too Much Drama
InMode looks cheap at 11.4x forward earnings, but flat growth, margin compression, and risks weigh on the stock. Click for more on INMD stock.
IN
NASDAQ · INMD
InMode Ltd.
Healthcare · Medical - Devices
$14.05
Up+$0.04 (+0.28%)
Updated Oct 3, 2026, 12:05 AM
SID Score
4.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 965.49M
- P/E ratio
- 5.12
- Dividend yield
- 0.00%
- 52-week range
- $12.72 – $16.74
- Volume
- 561.66K
- Avg. volume
- 671.59K
Price performance · INMD
INMD price history
1M range · 19 trading sessions · Daily adjusted prices
Prices through Oct 1, 2026
INMD closed at $14.05 after 19 trading sessions, down 5.77% for the selected period.
- Last close
- $14.05
- Period change
- -5.77%
- Period low
- $14.05
- Period high
- $14.91
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 1, 2026 | $14.08 | $14.18 | $13.9705 | $14.05 | 561.66K |
| Sep 30, 2026 | $14.21 | $14.215 | $14.11 | $14.17 | 378.73K |
| Sep 29, 2026 | $14.192 | $14.23 | $14.085 | $14.22 | 362.74K |
| Sep 28, 2026 | $14.26 | $14.29 | $14.19 | $14.205 | 201.74K |
| Sep 25, 2026 | $14.17 | $14.33 | $14.1601 | $14.26 | 412.41K |
| Sep 24, 2026 | $14.24 | $14.295 | $14.155 | $14.19 | 439.57K |
| Sep 23, 2026 | $14.43 | $14.435 | $14.18 | $14.19 | 381.84K |
| Sep 22, 2026 | $14.54 | $14.615 | $14.42 | $14.45 | 346.64K |
| Sep 21, 2026 | $14.38 | $14.51 | $14.3101 | $14.50 | 336.47K |
| Sep 18, 2026 | $14.49 | $14.52 | $14.29 | $14.35 | 758.09K |
| Sep 17, 2026 | $14.68 | $14.68 | $14.515 | $14.54 | 413.64K |
| Sep 16, 2026 | $14.81 | $14.81 | $14.33 | $14.58 | 958.19K |
| Sep 15, 2026 | $14.84 | $14.92 | $14.755 | $14.87 | 586K |
| Sep 14, 2026 | $14.94 | $14.97 | $14.835 | $14.89 | 249.84K |
| Sep 11, 2026 | $14.78 | $14.93 | $14.715 | $14.90 | 450.77K |
| Sep 10, 2026 | $14.72 | $14.84 | $14.60 | $14.77 | 825.02K |
| Sep 9, 2026 | $14.81 | $14.949 | $14.71 | $14.79 | 621.12K |
| Sep 8, 2026 | $14.80 | $14.945 | $14.72 | $14.81 | 624.41K |
| Sep 4, 2026 | $14.79 | $14.94 | $14.7719 | $14.91 | 449.39K |
Latest INMD news
The latest Smart Investors Daily articles mentioning INMD.
Stock researchCompany · Overview
Company
Market Activity
Research & News
INMD research
Overview
Company profile and research snapshot.
Company profile
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions in the United States. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF and Morpheus8. The majority of its revenue comes from the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Hold
- Average target
- $26.83
- Implied upside
- —
- Analysts
- 14
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 7, 2026 | Barclays | Overweight | — |
| May 7, 2026 | Baird | Neutral | — |
| Dec 17, 2025 | Canaccord Genuity | Hold | — |
| Nov 6, 2025 | UBS | Neutral | — |
| Oct 10, 2025 | Canaccord Genuity | Hold | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 9, 2026
InMode Advances RF Microneedling Comfort with the Launch of Morpheus8 Cool
InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announces the launch of Morpheus8 Cool, the next evolution of its renowned Morpheus8 technology. Available exclusively on the new expandable Morpheus8MAX platform, Morpheus8 Cool advances radiofrequency (RF) microneedling with enhanced comfort, precision, control, and safety.
Benzinga · Aug 11, 2026
InMode Says Haifa District Court Denied Steel Partners Affiliate's Request For Temporary Injunctive Relief In Its Entirety, Awarded Company Certain Costs
https://www.sec.gov/Archives/edgar/data/1742692/000117891326004040/zk2635934.htm
ChartMill · Aug 5, 2026
InMode (NASDAQ:INMD) Q2 Revenue Inline, EPS Beats; Shares Dip 2.5%
InMode Q2 revenue of $95.6M matches estimates, EPS beats at $0.35; shares slip 2.5% as growth stays flat.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
